Janus Henderson Group
PCRX icon

Janus Henderson Group’s Pacira BioSciences PCRX Stock Holding History

Janus Henderson Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527K Hold
23,319
– – ﹤0.01% 1990
2025
Q4 		$603K Hold
23,319
– – ﹤0.01% 1934
2025
Q3 		$601K Hold
23,319
– – ﹤0.01% 1920
2025
Q2 		$557K Hold
23,319
– – ﹤0.01% 1893
2025
Q1 		$581K Hold
23,319
– – ﹤0.01% 1880
2024
Q4 		$439K Hold
23,319
– – ﹤0.01% 2094
2024
Q3 		$351K Sell
23,319
-675,069
-97% -$11.5M ﹤0.01% 2191
2024
Q2 		$20M Buy
698,388
+96,328
+16% +$2.74M 0.01% 570
2024
Q1 		$17.6M Sell
602,060
-1,973
-0.3% -$60.6K 0.01% 582
2023
Q4 		$20.4M Buy
604,033
+66,330
+12% +$1.94M 0.01% 547
2023
Q3 		$16.5M Buy
537,703
+183,604
+52% +$6.62M 0.01% 571
2023
Q2 		$14.2M Buy
354,099
+334,292
+1,688% +$13.8M 0.01% 622
2023
Q1 		$808K Buy
19,807
+10,976
+124% +$437K ﹤0.01% 1745
2022
Q4 		$341K Buy
8,831
+1
+0% +$49 ﹤0.01% 1917
2022
Q3 		$470K Buy
8,830
+16
+0.2% +$890 ﹤0.01% 1982
2022
Q2 		$514K Sell
8,814
-9
-0.1% -$590 ﹤0.01% 1746
2022
Q1 		$674K Sell
8,823
-30,842
-78% -$2.06M ﹤0.01% 1722
2021
Q4 		$2.39M Sell
39,665
-22,278
-36% -$1.23M ﹤0.01% 1220
2021
Q3 		$3.47M Sell
61,943
-10,391
-14% -$599K ﹤0.01% 1142
2021
Q2 		$4.39M Sell
72,334
-4,981
-6% -$315K ﹤0.01% 1089
2021
Q1 		$5.42M Buy
+77,315
New +$5.52M ﹤0.01% 997
2016
Q1 		– Sell
-159,210
Closed -$12.2M – 846
2015
Q4 		$12.2M Buy
159,210
+25,708
+19% +$1.46M 0.1% 232
2015
Q3 		$5.49M Buy
133,502
+25,990
+24% +$1.59M 0.05% 330
2015
Q2 		$7.6M Buy
107,512
+9,612
+10% +$757K 0.06% 304
2015
Q1 		$8.7M Buy
97,900
+32,430
+50% +$3.29M 0.07% 302
2014
Q4 		$5.8M Buy
65,470
+11,578
+21% +$1.1M 0.04% 349
2014
Q3 		$5.22M Buy
+53,892
New +$5.24M 0.05% 267

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group's PCRX Position: Q1 2026 in Review

Janus Henderson Group held its Pacira BioSciences (PCRX) position steady in Q1 2026 at 23,319 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Janus Henderson Group first reported a position in PCRX in Q3 2014 and has held it in 27 quarters since. The position peaked at $20.4M in Q4 2023. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Janus Henderson Group held 23,319 shares of Pacira BioSciences worth $527K as of Q1 2026.
  • Janus Henderson Group left its Pacira BioSciences share count unchanged in Q1 2026.
  • Pacira BioSciences made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1990 holding.
  • Janus Henderson Group first reported a position in Pacira BioSciences in Q3 2014 and has held it in 27 quarters since.
  • Janus Henderson Group's Pacira BioSciences position peaked at $20.4M in Q4 2023.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.